Try our mobile app

Switch to company model in classical logic    *

General information

Country: GERMANY

Sector: Drug Manufacturers — Specialty and Generic

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women`s health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Website: evotec.com



Growth: Pretty weak revenue growth rate 9.4%, are preserved at an average historical level 9.4%

Profitability: LTM EBITDA margin is positive, +3.5%. On average the margin is decreasing unsteadily. Gross margin is low, +16.3%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 0% of quarters (showing a gain of -$0.20 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 40.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 5.0% higher than minimum and 80.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.0x by EV / Sales multiple , the company can be 90.0% undervalued

Key Financials (Download financials)

Ticker: EVO
Share price, USD:  (-1.9%)5.27
year average price 9.74  


year start price 9.43 2023-05-07

max close price 13.36 2023-07-20

min close price 5.02 2024-04-26

current price 5.27 2024-05-06
Common stocks: 176 702 653

Dividend Yield:  0.0%
FCF Yield LTM: 40.7%
EV / LTM EBITDA: 29.9x
EV / EBITDA annualized: 1.9x
Last revenue growth (y/y):  9.4%
Last growth of EBITDA (y/y):  -12.1%
Historical revenue growth:  9.4%
Historical growth of EBITDA:  -12.1%
EV / Sales: 1.0x
Margin (EBITDA LTM / Revenue): 3.5%
Fundamental value created in LTM:
Market Cap ($m): 931
Net Debt ($m): -213
EV (Enterprise Value): 718
Price to Book: 0.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-24Seeking Alpha

Evotec: Still A Speculative Buy After A Significant Decline

2024-04-24Market Watch

Evotec shares lose a third of their value on cloudy outlook

2024-04-17Accesswire

Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024

2024-01-22Seeking Alpha

Evotec SE (EVO) Business Update Conference Call (Transcript)

2024-01-22Accesswire

Evotec SE: Invitation to Conference Call

2024-01-04InvestorPlace

Why Is Evotec (EVO) Stock Down 12% Today?

2023-11-11Seeking Alpha

Evotec SE (EVO) Q3 2023 Earnings Call Transcript

2023-08-22Accesswire

Evotec SE Reports First Half-Year 2023 Results on 29 August 2023

2023-04-05Seeking Alpha

Evotec: Significantly Undervalued, Or Value Trap?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2022-12-31 2022-09-30 2022-06-30
symbol EVO EVO EVO EVO EVO EVO
reportedCurrency EUR EUR EUR EUR EUR EUR
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-12-31 2023-09-30 2023-08-29 2023-05-12 2022-09-30 2022-06-30
acceptedDate 2023-12-29 19:00:00 2023-09-29 20:00:00 2023-08-29 09:59:07 2023-05-12 17:29:36 2022-09-29 20:00:00 2022-06-29 20:00:00
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q4 Q3 Q2
revenue 201M 196M 170M 241M 174M 172M
costOfRevenue 164M 158M 124M 158M 145M 141M
grossProfit 38M 38M 46M 82M 28M 31M
grossProfitRatio 0.187 0.193 0.272 0.343 0.163 0.179
researchAndDevelopmentExpenses 20M 18M 12M 21M 18M 19M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 42M 39M 46M 46M 42M 36M
otherExpenses 0 4M 11M -23M -19M -20M
operatingExpenses 62M 50M 83M 45M 42M 35M
costAndExpenses 226M 208M 207M 203M 187M 176M
interestIncome 1M 2M 3M 3M 3M 1M
interestExpense 3M 4M 3M 2M 3M 4M
depreciationAndAmortization 18M 2M 10M -2M -636 000 -3M
ebitda 50M -10M -26M 36M -14M -7M
ebitdaratio 0.246 -0.050 -0.152 0.148 -0.081 -0.038
operatingIncome -25M -12M -36M 38M -14M -4M
operatingIncomeRatio -0.122 -0.062 -0.213 0.157 -0.078 -0.022
totalOtherIncomeExpensesNet 10M -17M 16M -55M -30M -21M
incomeBeforeTax -15M -30M -20M -18M -43M -24M
incomeBeforeTaxRatio -0.074 -0.152 -0.120 -0.073 -0.249 -0.141
incomeTaxExpense -8M 9M -6M 10M 4M 4M
netIncome -16M -39M -15M -27M -47M -28M
netIncomeRatio -0.080 -0.198 -0.088 -0.113 -0.272 -0.162
eps -0.091 -0.220 -0.084 -0.077 -0.130 -0.079
epsdiluted -0.091 -0.220 -0.084 -0.077 -0.130 -0.079
weightedAverageShsOut 177M 177M 177M 353M 353M 353M
weightedAverageShsOutDil 177M 177M 177M 353M 353M 353M
link Link Link
finalLink Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-04-07 2022-12-31 2022-09-30 2022-06-30
symbol EVO EVO EVO EVO EVO EVO EVO
reportedCurrency EUR EUR EUR USD USD EUR EUR
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2023-12-31 2023-09-30 2023-08-29 2023-04-07 2023-05-12 2022-09-30 2022-06-30
acceptedDate 2023-12-29 19:00:00 2023-09-29 20:00:00 2023-08-29 09:59:07 2023-04-07 10:53:31 2023-05-12 17:29:36 2022-09-29 20:00:00 2022-06-29 20:00:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 511M 499M 460M 0 415M 464M 697M
shortTermInvestments 93M 120M 173M 0 315M 365M 194M
cashAndShortTermInvestments 604M 619M 633M 0 730M 829M 891M
netReceivables 204M 219M 291M 0 257M 188M 150M
inventory 31M 32M 33M 0 30M 31M 29M
otherCurrentAssets 64M 69M 70M 0 40M 48M 75M
totalCurrentAssets 903M 939M 1 026M 0 1 074M 1 096M 1 144M
propertyPlantEquipmentNet 807M 764M 721M 0 650M 600M 560M
goodwill 276M 0 277M 0 275M 278M 259M
intangibleAssets 15M 291M 15M 0 24M 26M 27M
goodwillAndIntangibleAssets 291M 291M 293M 0 299M 304M 286M
longTermInvestments 142M 152M 161M 0 150M 189M 217M
taxAssets 61M 10M 11M 0 10M 16M 18M
otherNonCurrentAssets 95M 99M 89M 0 74M 57M 68M
totalNonCurrentAssets 1 396M 1 315M 1 275M 0 1 184M 1 167M 1 149M
otherAssets 1.000 0 0 0 0 0 0
totalAssets 2 299M 2 255M 2 301M 0 2 257M 2 263M 2 294M
accountPayables 134M 97M 106M 0 97M 84M 81M
shortTermDebt 149M 144M 59M 0 16M 14M 14M
taxPayables 6M 8M 10M 0 9M 10M 9M
deferredRevenue 108M 119M 150M 0 137M 147M 150M
otherCurrentLiabilities 73M 74M 173M 0 87M 96M 75M
totalCurrentLiabilities 465M 434M 488M 0 338M 341M 321M
longTermDebt 477M 444M 17M 0 490M 478M 469M
deferredRevenueNonCurrent 155M 199M 220M 0 206M 180M 193M
deferredTaxLiabilitiesNonCurrent 65M 19M 19M 0 19M 17M 17M
otherNonCurrentLiabilities 17M 18M 383M 0 17M 448M 452M
totalNonCurrentLiabilities 715M 680M 639M 0 732M 693M 698M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 189M 0 0 0 177M 165M 157M
totalLiabilities 1 179M 1 114M 1 127M 0 1 070M 1 034M 1 018M
preferredStock 0 0 12M 0 0 0 0
commonStock 177M 177M 177M 0 177M 177M 177M
retainedEarnings -476M -483M -448M 0 -392M -365M -317M
accumulatedOtherComprehensiveIncomeLoss -18M -0.000 -12M 0 -37M -21M -19M
othertotalStockholdersEquity 1 437M 1 446M 1 445M 0 1 440M 1 438M 1 435M
totalStockholdersEquity 1 120M 1 141M 1 174M 0 1 187M 1 229M 1 276M
totalEquity 1 120M 1 141M 1 174M 0 1 187M 1 229M 1 276M
totalLiabilitiesAndStockholdersEquity 2 299M 2 255M 2 301M 0 2 257M 2 263M 2 294M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 2 299M 2 255M 2 301M 0 2 257M 2 263M 2 294M
totalInvestments 235M 271M 334M 0 465M 554M 411M
totalDebt 626M 589M 534M 0 507M 492M 483M
netDebt 115M 89M 74M 0 92M 28M -214M
link Link Link Link
finalLink Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2022-12-31 2022-09-30 2022-06-30
symbol EVO EVO EVO EVO EVO EVO
reportedCurrency EUR EUR EUR EUR EUR EUR
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-12-31 2023-09-30 2023-08-29 2023-05-12 2022-11-09 2022-06-30
acceptedDate 2023-12-29 19:00:00 2023-09-29 20:00:00 2023-08-29 09:59:07 2023-05-12 17:29:36 2022-11-09 06:01:01 2022-06-29 20:00:00
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q4 Q3 Q2
netIncome -16M -39M -15M -27M -47M -28M
depreciationAndAmortization 92M -45M 22M 0 0 0
deferredIncomeTax -5M 0 0 0 0 0
stockBasedCompensation 10M 0 0 0 0 0
changeInWorkingCapital 16M 11M -18M -24M -35M 135M
accountsReceivables 0 0 0 0 0 0
inventory 0 0 0 0 0 0
accountsPayables 0 0 0 0 0 0
otherWorkingCapital 16M 11M -18M 0 0 0
otherNonCashItems 24M 94M 8M 18M 78M 70M
netCashProvidedByOperatingActivities 19M 21M -3M -34M -4M 177M
investmentsInPropertyPlantAndEquipment -66M -46M -52M -24M -76M -38M
acquisitionsNet 1M -6M 0 -32M 12M -44M
purchasesOfInvestments -36M -4M 0 -24M -170M -75M
salesMaturitiesOfInvestments 59M 42M 0 100M 8M 49M
otherInvestingActivites 6M -2M 66M 0 -2M -2M
netCashUsedForInvestingActivites -37M -16M 14M 19M -228M -111M
debtRepayment -40M -87M 0 -2M -5M -46M
commonStockIssued -14 000 0 0 0 0 10000.000
commonStockRepurchased -14 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -13M 131M 5M 0 -1000.000 6M
netCashUsedProvidedByFinancingActivities 31M 43M 5M -2M -5M -41M
effectOfForexChangesOnCash -2M -9M 5M -32M 4M 11M
netChangeInCash 12M 40M 45M -49M -233M 37M
cashAtEndOfPeriod 511M 499M 460M 415M 464M 697M
cashAtBeginningOfPeriod 499M 460M 415M 464M 697M 660M
operatingCashFlow 19M 21M -3M -34M -4M 177M
capitalExpenditure -66M -46M -52M -24M -76M -38M
freeCashFlow -47M -25M -55M -58M -80M 139M
link Link Link Link
finalLink Link Link Link

Earning call transcript

2024 q1
2024-04-24 ET (fiscal 2023 q4)
2023 q4
2024-01-22 ET (fiscal 2023 q1)
2023 q3
2023-11-11 ET (fiscal 2023 q3)
2023 q1
2023-03-28 ET (fiscal 2022 q4)
2022 q3
2022-11-12 ET (fiscal 2022 q3)
2022 q2
2022-08-13 ET (fiscal 2022 q2)

Press-releases

Show financial reports only

2024-04-24 05:20 ET
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
2024-04-23 19:00 ET
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
2024-04-18 11:45 ET
Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments
2024-04-18 11:27 ET
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
2024-04-17 13:15 ET
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
2024-04-17 05:50 ET
Evotec welcomes Aurélie Dalbiez as Chief People Officer
2024-03-06 06:50 ET
Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic
2024-02-07 07:00 ET
Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV
2024-01-22 07:00 ET
Evotec SE: Invitation to Conference Call
2024-01-10 14:45 ET
Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies
2024-01-08 06:50 ET
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
2024-01-04 06:45 ET
Evotec and Owkin Enter an A.I.-Powered Strategic Partnership to Accelerate Therapeutics Pipeline in Oncology and I&I
2024-01-03 17:45 ET
Evotec Announces CEO Transition
2023-12-19 07:00 ET
Evotec receives US$ 2.5 M Grant to Leverage Human iPSC-Derived Teratogenicity Platform for Global Health Programmes
2023-12-14 07:00 ET
Evotec Enters Partnership with Charité to Expand Molecular Patient Database in Autoimmune Diseases
2023-12-06 06:50 ET
Evotec-partner Jingxin Receives Approval for EVT201 in China
2023-11-15 06:50 ET
Evotec Presents Precision Medicine Platforms for Accelerated Pipeline Building at Capital Markets Day
2023-11-08 06:20 ET
Evotec SE Reports Results for the First Nine Months 2023 and Provides Corporate Update
2023-11-07 06:50 ET
Evotec and Dewpoint Therapeutics Enter Strategic Partnership in Oncology
2023-11-07 06:30 ET
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
2023-10-05 06:35 ET
Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'
2023-09-27 05:50 ET
Evotec SE: Launch of Partnering Agreement to Strengthen Biotech Innovators in Shared R&D Economy
2023-09-26 12:00 ET
Evotec and Novo Nordisk Launch LAB eN² to Accelerate Translation in Cardiometabolic Diseases
2023-08-29 05:20 ET
Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates
2023-08-22 12:20 ET
Evotec SE Reports First Half-Year 2023 Results on 29 August 2023
2023-07-27 18:05 ET
Evotec Provides Update on Financial Impact of Cyber-Attack
2023-07-11 05:50 ET
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
2023-07-05 05:50 ET
Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program
2023-06-29 06:00 ET
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
2023-06-20 15:30 ET
Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items
2023-06-05 05:50 ET
Evotec Presents Sustainability Strategy
2023-06-02 06:00 ET
Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
2023-05-12 22:30 ET
Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
2023-05-09 18:55 ET
Just - Evotec Biologics Enters Strategic Biosimilars Partnership with Sandoz
2023-05-09 18:30 ET
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
2023-04-24 20:05 ET
Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
2023-04-10 12:15 ET
Evotec SE Provides Update on Cyber Attack
2023-04-07 13:20 ET
Cyber Attack on Evotec
2023-03-28 09:20 ET
Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
2023-03-28 05:30 ET
Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
2023-03-24 07:00 ET
Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
2023-03-21 11:10 ET
Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023
2023-03-16 07:05 ET
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
2023-02-10 07:00 ET
Evotec Receives € 150 m Loan from European Investment Bank
2023-02-09 07:00 ET
Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership
2023-02-07 07:00 ET
Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
2023-01-26 07:00 ET
Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies
2023-01-10 12:00 ET
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
2022-12-16 08:40 ET
Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
2022-11-09 06:20 ET
Evotec SE Reports Results for the First Nine Months 2022 and Provides Corporate Update
2022-11-03 11:15 ET
Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022
2022-11-03 07:00 ET
Evotec Completes Acquisition of Central Glass Germany
2022-11-02 07:00 ET
Evotec Presents Paradigm Shift in Biologics at Capital Markets Day
2022-10-28 07:20 ET
Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic Institutions
2022-10-25 05:50 ET
Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune Diseases
2022-10-18 06:00 ET
Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World
2022-10-17 11:15 ET
Evotec and TIAP Expand LAB150 BRIDGE Partnership to Include Amgen
2022-10-17 11:00 ET
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
2022-09-21 10:00 ET
Adapsyn Bioscience enters into strategic collaboration with Evotec
2022-09-20 05:50 ET
Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
2022-09-16 13:25 ET
Evotec Initiates Ground-Breaking for New Biologics Facility J.POD(R) Toulouse, France (EU)
2022-09-01 11:33 ET
Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share
2022-08-25 05:50 ET
Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany
2022-08-11 05:40 ET
Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates
2022-08-10 05:55 ET
Just - Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
2022-08-04 09:30 ET
Evotec SE Reports First Half-year 2022 Results on 11 August 2022
2022-07-06 05:50 ET
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
2022-07-06 05:50 ET
Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance
2022-07-05 05:50 ET
Evotec Completes Acquisition of Rigenerand
2022-06-22 14:45 ET
Evotec SE Reports Results of Annual General Meeting 2022
2022-06-14 05:50 ET
Evotec Enters a Drug Discovery Collaboration with Janssen
2022-05-30 06:00 ET
Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand
2022-05-19 05:50 ET
Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology
2022-05-17 11:00 ET
Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes
2022-05-17 05:50 ET
Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes
2022-05-10 14:55 ET
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership
2022-05-10 14:45 ET
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
2022-05-04 12:45 ET
Evotec SE to Announce Results for the First Quarter 2022 on 11 May 2022
2022-04-12 05:45 ET
Evotec SE Fiscal Year 2021 Results: 'Setting the Pace' on the Data-Driven R&D Autobahn to Cures
2022-04-08 05:55 ET
Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
2022-04-05 12:55 ET
Evotec SE to Announce Results for Fiscal Year 2021 on 12 April 2022
2022-03-21 07:00 ET
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
2022-03-02 06:50 ET
Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day
2022-03-01 06:50 ET
Evotec Expands Molecular Patient Database with Unique Nephrotic Syndrome Cohort from the University of Bristol
2022-02-15 14:00 ET
IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SE
2022-02-04 12:45 ET
Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets
2022-01-25 06:55 ET
Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology
2022-01-18 07:00 ET
Evotec and Lilly Enter into Drug Discovery Collaboration in Metabolic Diseases
2022-01-11 07:00 ET
Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach
2022-01-03 06:55 ET
Evotec Receives € 7.5 m Grant for Development of COVID-19 Therapeutic
2021-12-16 07:00 ET
Evotec Receives US$ 18 M Grant for Women's Health
2021-11-18 12:00 ET
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
2021-11-18 06:50 ET
Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership
2021-11-11 06:30 ET
Evotec SE Reports Results for the First Nine Months 2021 and Provides Corporate Update
2021-11-10 07:00 ET
Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
2021-11-09 14:55 ET
Evotec SE Announces Closing of Public Offering

SEC forms

Show financial reports only

SEC form 6
2024-04-24 13:22 ET
Evotec SE published news for 2024 q1
SEC form 6
2024-04-24 13:22 ET
Evotec SE published news for 2024 q1
SEC form 6
2024-04-24 13:22 ET
Evotec SE published news for 2024 q1
SEC form 6
2024-04-24 13:22 ET
Evotec SE published news for 2024 q1
SEC form 6
2024-04-23 17:13 ET
Evotec SE published news for 2024 q1
SEC form 6
2024-04-23 17:13 ET
Evotec SE published news for 2024 q1
SEC form 6
2024-04-23 17:13 ET
Evotec SE published news for 2024 q1
SEC form 6
2024-04-08 09:40 ET
Evotec SE published news for 2024 q1
SEC form 6
2024-04-08 09:40 ET
Evotec SE published news for 2024 q1
SEC form 6
2024-01-03 16:59 ET
Evotec SE published news for 2023 q4
SEC form 6
2024-01-03 16:59 ET
Evotec SE published news for 2023 q4
SEC form 6
2024-01-03 16:59 ET
Evotec SE published news for 2023 q4
SEC form 6
2023-11-08 06:02 ET
Evotec SE reported for 2023 q3
SEC form 6
2023-08-29 09:59 ET
Evotec SE reported for 2023 q2
SEC form 6
2023-07-27 16:32 ET
Evotec SE published news for 2023 q2
SEC form 6
2023-06-21 16:14 ET
Evotec SE published news for 2023 q1
SEC form 6
2023-06-20 13:23 ET
Evotec SE published news for 2023 q1
SEC form 6
2023-05-12 17:29 ET
Evotec SE published news for 2023 q1
SEC form 6
2023-05-12 16:03 ET
Evotec SE published news for 2023 q1
SEC form 6
2023-05-09 16:37 ET
Evotec SE published news for 2023 q1
SEC form 6
2023-05-02 15:24 ET
Evotec SE published news for 2023 q1
SEC form 6
2023-04-07 10:53 ET
Evotec SE published news for 2023 q1
SEC form 6
2023-04-05 15:19 ET
Evotec SE published news for 2023 q1
SEC form 6
2023-03-28 10:25 ET
Evotec SE published news for 2022 q4
SEC form 6
2023-03-28 10:11 ET
Evotec SE published news for 2022 q4
SEC form 6
2023-02-07 09:23 ET
Evotec SE published news for 2022 q4
SEC form 6
2022-11-16 06:00 ET
Evotec SE published news for 2022 q3
SEC form 6
2022-11-09 06:01 ET
Evotec SE published news for 2022 q3
SEC form 6
2022-10-06 12:40 ET
Evotec SE published news for 2022 q3
SEC form 6
2022-08-11 06:04 ET
Evotec SE published news for 2022 q2
SEC form 6
2022-06-24 13:53 ET
Evotec SE published news for 2022 q1
SEC form 6
2022-06-23 11:00 ET
Evotec SE published news for 2022 q1
SEC form 6
2022-06-09 06:01 ET
Evotec SE published news for 2022 q1
SEC form 6
2022-06-07 11:35 ET
Evotec SE published news for 2022 q1
SEC form 6
2022-06-03 14:22 ET
Evotec SE published news for 2022 q1
SEC form 6
2022-05-11 06:02 ET
Evotec SE published news for 2022 q1
SEC form 6
2022-05-10 12:52 ET
Evotec SE published news for 2022 q1
SEC form 6
2022-04-26 06:48 ET
Evotec SE published news for 2022 q1
SEC form 6
2022-04-12 08:15 ET
Evotec SE published news for 2022 q1
SEC form 6
2022-02-04 09:39 ET
Evotec SE published news for 2021 q4
SEC form 6
2021-11-12 06:06 ET
Evotec SE published news for 2021 q3